An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that the first-to-market therapy ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
An inherent principle of publication is that others should be able to replicate and build upon the authors' published claims. A condition of publication in a Nature Portfolio journal is that authors ...
Saudi Azm reports SAR 37.4M profit in FY 2024/25; Q4 at SAR 12.1M 12 M 2025 Saudi Azm profit leaps 43% to SAR 25.8M in 9M 2024/25; Q3 at SAR 8.4M 9 M 2025 Saudi Azm net profit leaps 30% to SAR 17.4M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback